Ipamorelin, closely examined
Lifted peptides, timed against a meal
I followed the rise in growth hormone and wound up at a table: a trial of eating again after bowel surgery.
Early hormone results
The early ipamorelin experiments gave “selective” a concrete meaning. In rat pituitary cells, rats and swine, it released growth hormone while ACTH and cortisol stayed at levels no higher than those seen with growth-hormone-releasing hormone. That gave the molecule a distinctive pharmacological identity.
Then came healthy male volunteers and a discrete growth hormone pulse, peaking at about 40 minutes after intravenous administration. A signal had been lifted, and its timing could be described. The timing has an obvious appeal. Its eventual clinical destination surprised me.
Ipamorelin’s selective start follows those experiments, including the small human study and the word “selective” that has so much work put upon it.
Postoperative recovery
The published clinical test concerned adults recovering from bowel resection. Its primary endpoint—the result the trial chiefly set out to test—was time to the first tolerated meal. In the randomized trial of 114 adults, the median was 25.3 hours with ipamorelin and 32.6 hours with placebo; p=0.15, and the primary endpoint was missed.
An ordinary meal makes a wonderfully concrete scientific ambition. A question that ends at a table earns my interest far more readily than an adjective such as “optimised.” Yet the appeal of the question cannot rescue the outcome: efficacy was not demonstrated in that trial.
The bowel-surgery article follows the gut experiments into that result. It is the centre of this collection because the question was both useful and answerable, even though the answer disappointed.
Weight, bone and safety
Other experiments tried to move different quantities. In adult female rats, bone mineral content increased while cortical volumetric mineral density stayed unchanged. That distinction deserves more care than a broad claim about stronger bones. A ferret experiment on chemotherapy-associated weight loss pursued weight preservation, another very particular aim. These are animal findings.
My enthusiasm runs toward that specificity: an identified species, a measured change, an awkward qualification. Weight and bone puts those results beside one another without turning them into a human body-transformation story.
There is also a separate safety examination. The published perioperative trial supplies a short observation window; a gerontology review describes gaps in ipamorelin’s long-term safety data and systematic validation. The hormone result earns my curiosity; the safety record leaves me unconvinced.